Clinical Trial Update: A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 open-label trial to evaluate the relative and absolute bioavailability of Cotadutide in healthy subjects, sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Non-alcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Cotadutide (cotadutide)

Snippet

Sponsor: AstraZeneca | Conditions: Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Status: COMPLETED